This tool is designed to help streamline the continuum of care for MDS patients, from diagnosis and staging through to treatment.

It features a comprehensive algorithm, which is the outcome of a Canada-wide physician consensus on best practices in MDS management. Ultimately it will serve to support physicians at key decision points in their treatment of MDS patients.

MDS Clear Path
START
FRANÇAIS
The content of this program was supported by an unrestricted educational grant from Bristol Myers Squibb (BMS). MDS Clear Path has been developed and approved by a Steering Committee with the input of over 60 Canadian physicians. Members of this Steering Committee are Dr. Heather Leitch, Dr. Harold Olney, Dr. April Shamy, Dr. Brian Leber, and Dr. Richard Wells. The opinions expressed are solely those of the Steering Committee members. The content is specifically intended to be used by qualified physicians/medical professionals, to assist them in the management of MDS patients. The MDS Clear Path does not substitute, nor is it intended to substitute for the medical advice of an appropriately qualified and licensed physician or other healthcare provider. Use of the application is undertaken entirely on your own responsibility as a healthcare professional. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. The digital formats of the MDS Clear Path have been completed by The Adpharm Inc. (a healthcare communications company) through funding from BMS. The sole purpose was to deliver the content of the original MDS Clear Path in a user friendly, digital format. No content was modified in the transition to a digital format. All digital formats are the property of the Canadian Consortium on MDS (CCMDS). This presentation may include indications and treatment regimens that are not authorized in Canada. Please refer to current product monographs for complete indication and safety information.

Contact Us

info@synapsemedcom.ca